- Report
- January 2026
- 378 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- August 2025
- 150 Pages
Global
From €5165EUR$5,950USD£4,478GBP
- Report
- January 2026
- 186 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 186 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
- 186 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- January 2026
Global
From €4253EUR$4,900USD£3,688GBP
- Report
- July 2025
Global
From €4253EUR$4,900USD£3,688GBP
- Report
- January 2026
- 287 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 197 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 194 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 196 Pages
Global
From €5078EUR$5,850USD£4,402GBP
- Report
- January 2026
- 187 Pages
Global
From €3419EUR$3,939USD£2,964GBP
- Report
- October 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- September 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- July 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- July 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 175 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- April 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- March 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP
- Report
- March 2025
- 250 Pages
Global
From €3897EUR$4,490USD£3,379GBP

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more